இறுதிப்புள்ளி நிகழ்ச்சிகள் மட்டும் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
KVD900 Generally Safe and Well-Tolerated -
Conference Call to Discuss Trial Results Today at 8:30 a.m. ET -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) attacks.
We are very excited to share this positive data which shows that KVD900 is the first oral therapy to achieve clinical efficacy results comparable to current injectable therapies, while also demonstrating a promising safety and tolerab ....

United States , Kathryn Morris , Andrew Crockett , Leah Monteiro , Drug Administration , Corporate Communications Investor Relations , Kalvista Pharmaceuticals Inc , Yates Network , European Medicines Agency , Endpoint Shows Only , Rescue Medication , Hereditary Angioedema , Discuss Trial Results Today , Vista Pharmaceuticals , Chief Executive Officer , Conference Call , Fast Track , Pediatric Investigational Plan , Kalvista Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , க்யாத்ரிந் மோரிஸ் , ஆண்ட்ரூ குரோக்கெட் , லியா மான்டீரோ , பெருநிறுவன தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் , யேட்ஸ் வலைப்பின்னல் , இறுதிப்புள்ளி நிகழ்ச்சிகள் மட்டும் ,